GP与NP方案治疗晚期非小细胞肺癌的临床对比观察

目的评价吉西他滨联合顺铂(GP)方案与诺维本联合顺铂(NP)方案治疗晚期非小细胞肺癌的疗效及毒副反应。方法经病理组织学或细胞学证实的62例非小细胞肺癌患者,随机分为两组,吉西他滨联合顺铂组(A组)31例,以吉西他滨1 200 mg/m2静滴,第1、8天,顺铂80 mg/m2静滴,第1天;诺维本联合顺铂组(B组)31例,以诺维本25mg/m2静滴,第1、8天,顺铂80 mg/m2静滴,第1天。两方案均每3周重复,3周期以上评价疗效。结果A、B两组的有效率分别为48.3%(15/31)、51.1%(16/31),组间无显著性差异(P>0.05);中位疾病进展时间分别为4.8个月和3.8个月,组间有显著性差异(P<0.05);一年生存率A组为45.2%、B组为41.9%,组间无显著性差异(P>0.05)。A组Ⅲ~Ⅳ度血小板减少高于B组,但Ⅲ~Ⅳ度白细胞减少及脱发明显低于B组。结论A、B两组在有效率、中位生存期及一年生存率方面均较接近,但中位疾病进展时间吉西他滨组略占优势。

The Clinical Observation of Gemcitabine or Vinorelbine Combined with Cisplatin in the treatment of advanced patients with non-small-cell lung cancer

Objective To observe the efficacy,toxicity and side effects of the two combinations of gemcitabine cisplatin and vinorelbine cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods 62 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into groups randomly, each group have 31 patients. The group A with 31 patients received gencitabine 1 200 mg/m2 on d l,8 and cisplatin 80 mg/m2 in the first day ;the group B with another 31 patients received vinorelbine 25 mg/m2 in the d l ,8 and cisplatin 80 mg/m2 in the first day. Both regiments had 21-day cycle,i e., three weeks repeated and the efficacy was observed after 3 period. Results The efficacy of group A and B was 48.3% (15/31) and 51.1%(16/31) respectively.. There was no significant differece (P>0.005) between two groups from the view of accounting. The median ailment development time were 4.8 and 3.8 months for group A and B ,respectively and there had some accounting difference (P>0.005) The median survival time were 10.5 months and no significant difference (P>0.005) .Finaly the l-year survival rate was 45.2% for group A and 41.9% for group B. there was also no significant difference(P>0.05).Thrombocytopenia with group A was higher than that of group B but the leucopeniano and alopecia with group A were apparently lower than that or group B. Conclusion There was no significant differece with group A and B on efficacy ,median survival time and l-year survival rate ,but there was a little advantage with group A on median ailment development time .